Illumina Stock Forecast, Price & News

18 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Illumina in the last year. There are currently 4 sell ratings, 8 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" Illumina stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ILMN, but not buy additional shares or sell existing shares.
View analyst ratings for Illumina or view top-rated stocks.

Wall Street analysts have given Illumina a "Hold" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Illumina wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

Illumina saw a decline in short interest in January. As of January 29th, there was short interest totaling 4,150,000 shares, a decline of 19.1% from the January 14th total of 5,130,000 shares. Based on an average daily volume of 1,110,000 shares, the days-to-cover ratio is currently 3.7 days. Approximately 2.9% of the company's stock are sold short.
View Illumina's Short Interest.

Illumina is scheduled to release its next quarterly earnings announcement on Thursday, April 29th 2021.
View our earnings forecast for Illumina.

Illumina, Inc. (NASDAQ:ILMN) posted its quarterly earnings results on Thursday, February, 11th. The life sciences company reported $1.22 earnings per share for the quarter, beating the Zacks' consensus estimate of $1.11 by $0.11. Illumina had a trailing twelve-month return on equity of 15.93% and a net margin of 19.70%.
View Illumina's earnings history.

Illumina's stock was trading at $246.01 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization (WHO). Since then, ILMN stock has increased by 62.4% and is now trading at $399.61.
View which stocks have been most impacted by COVID-19.

Illumina issued an update on its FY 2021 After-Hours earnings guidance on Thursday, February, 11th. The company provided earnings per share (EPS) guidance of 5.10-5.35 for the period, compared to the Thomson Reuters consensus estimate of $6.11. The company issued revenue guidance of $3.79-3.887 billion, compared to the consensus revenue estimate of $3.9 billion.

18 Wall Street analysts have issued 12 month price targets for Illumina's shares. Their forecasts range from $280.00 to $570.00. On average, they anticipate Illumina's share price to reach $364.00 in the next twelve months. This suggests that the stock has a possible downside of 8.9%.
View analysts' price targets for Illumina or view top-rated stocks among Wall Street analysts.

496 employees have rated Illumina CEO Francis deSouza on Glassdoor.com. Francis deSouza has an approval rating of 92% among Illumina's employees. This puts Francis deSouza in the top 30% of approval ratings compared to other CEOs of publicly-traded companies.

Some companies that are related to Illumina include Thermo Fisher Scientific (TMO), Agilent Technologies (A), Mettler-Toledo International (MTD), Bio-Rad Laboratories (BIO), Waters (WAT), PerkinElmer (PKI), Bio-Techne (TECH), Charles River Laboratories International (CRL), Bruker (BRKR), Pacific Biosciences of California (PACB), Luminex (LMNX), Fluidigm (FLDM), Harvard Bioscience (HBIO), aTyr Pharma (LIFE) and BG Medicine (BGMD).
View all of ILMN's competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Illumina investors own include NVIDIA (NVDA), Alibaba Group (BABA), Tesla (TSLA), Netflix (NFLX), The Walt Disney (DIS), PayPal (PYPL), salesforce.com (CRM), Adobe (ADBE), Visa (V) and Micron Technology (MU).

Illumina trades on the NASDAQ under the ticker symbol "ILMN."

Illumina's stock is owned by many different retail and institutional investors. Top institutional investors include Baillie Gifford & Co. (13.59%), Edgewood Management LLC (4.76%), Sands Capital Management LLC (2.02%), Janus Henderson Group PLC (1.88%), Northern Trust Corp (1.14%) and Norges Bank (1.06%). Company insiders that own Illumina stock include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Omead Ostadan, Phillip G Febbo, Robert P Ragusa, Robert S Epstein, Sam Samad and Susan H Tousi.
View institutional ownership trends for Illumina.

ILMN stock was sold by a variety of institutional investors in the last quarter, including Select Equity Group L.P., WCM Investment Management LLC, WCM Investment Management LLC, Sumitomo Mitsui Trust Holdings Inc., Swedbank, First Trust Advisors LP, Principal Financial Group Inc., and Principal Financial Group Inc.. Company insiders that have sold Illumina company stock in the last year include Aimee L Hoyt, Charles Dadswell, Frances Arnold, Francis A Desouza, Jay T Flatley, Karen K Mcginnis, Mostafa Ronaghi, Oene Mark Van, Phillip G Febbo, Robert P Ragusa, Sam Samad, and Susan H Tousi.
View insider buying and selling activity for Illumina or view top insider-selling stocks.

ILMN stock was acquired by a variety of institutional investors in the last quarter, including Baillie Gifford & Co., Janus Henderson Group PLC, Norges Bank, Ownership Capital B.V., Korea Investment CORP, Ardevora Asset Management LLP, Northern Trust Corp, and Ensemble Capital Management LLC.
View insider buying and selling activity for Illumina or or view top insider-buying stocks.

Shares of ILMN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of ILMN stock can currently be purchased for approximately $399.61.

Illumina has a market capitalization of $58.30 billion and generates $3.54 billion in revenue each year. The life sciences company earns $1.00 billion in net income (profit) each year or $6.57 on an earnings per share basis.

Illumina employs 7,700 workers across the globe.

The following companies are subsidiares of Illumina: Advanced Liquid Logic, Advanced Liquid Logic Inc., Affomix Corporation, BlueBee, BlueGnome Ltd, BlueGnome Ltd., Conexio Genomics, Conexio Genomics Pty Ltd., Edico Genome, Edico Genome Corp., Enancio, Epicentre Biotechnologies, Epicentre Technologies Corporation, FC Ops Corp., GenoLogics, Grail, Helixis, Illumina (China) Scientific Co Ltd, Illumina AB, Illumina Australia Pty. Ltd., Illumina Belgium BVBA, Illumina Brasil Produtos de Biotecnologia Ltda., Illumina Cambridge Ltd., Illumina Canada Inc., Illumina Denmark ApS, Illumina Finland Oy, Illumina France Holding Sarl, Illumina France Sarl, Illumina GmbH, Illumina Hong Kong Limited, Illumina Iceland ehf, Illumina India Biotechnology Private Limited, Illumina Ireland Commercial Limited, Illumina Italy S.r.l., Illumina K.K. Japan, Illumina Korea Ltd., Illumina Netherlands B.V., Illumina New Zealand Limited, Illumina Norway AS, Illumina Productos de Espana S.L.U., Illumina Rus, Illumina Shanghai (Trading) Co Ltd, Illumina Shanghai (Trading) Co. Ltd., Illumina Singapore Pte. Ltd., Illumina Switzerland GmbH, Illumina US Manufacturing Operations Inc., NextBio, Solexa, Verinata Health, Verinata Health Inc., and thromboDx BV.

Illumina was founded in 1998.

The official website for Illumina is www.illumina.com.

Illumina is headquartered at 200 ILLUMINA WAY, SAN DIEGO CA, 92122.

Illumina's mailing address is 200 ILLUMINA WAY, SAN DIEGO CA, 92122. The life sciences company can be reached via phone at 858-202-4500 or via email at [email protected]